Gadeer Ali Taha

Dr. Gadeer Ali Taha


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2023 in Viruses
Verified
Journal Article
Open access
PDF file
GTGadeer Ali Taha
Gadeer Ali Taha
ELEzra Levy
Ezra Levy
NANaim Abu-Freha
Naim Abu-Freha
Hepatitis C Virus (HCV) infection is a leading etiology of liver cirrhosis and its associated complications, namely, decompensated cirrhosis. As such, hepatitis C potentially necessitates liver transplantation and may result in death. Recently, HCV treatment has evolved. Current HCV treatment is effective in curing HCV; some of the agents are pan-genotypic. Numerous countries have adopted an initiative to eliminate HCV. Achieving elimination poses many challenges; it requires improved availability and accessibility of pan-genotypic therapy. Barriers exist at the level of the collective healthcare system and at the level of the individual healthcare providers and patients. Therefore, organized national and local efforts are needed. Surmounting these barriers calls for interventions concerning screening, linkage to care, and treatment delivery. Pertinent barriers include inadequate availability of screening, ill-equipped laboratory testing before treatment, and insufficient access to treatment. Interventions should seek to decentralize laboratory testing and treatment provision, increase funding for resources and personnel, and spread awareness. Special consideration should be allocated to at-risk populations, such as intravenous drug users, refugees, and prisoners. Computerized medical filing and telemedicine have the potential to refine HCV management by enhancing detection, availability, accessibility, and cost-effectiveness.

12 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
NANaim Abu-Freha
Naim Abu-Freha
BCBracha Cohen
Bracha Cohen
SWSarah Weissmann
Sarah Weissmann
RHReut Hizkiya
Reut Hizkiya
RHRim Abu hamid
Rim Abu hamid
MGMichal Gordon
Michal Gordon
Sex-based medicine is an important emerging discipline within medicine. We investigated the clinical characteristics, complications, and outcomes of Nonalcoholic Fatty Liver Disease (NAFLD) in females compared to males. Demographics, comorbidities, malignancy, complications, outcomes, and all-cause mortality of NAFLD patients older than 18 years were analyzed. The data were extracted using the MDClone platform from “Clalit” in Israel. A total of 111,993 (52.8%) of the study subjects were females with an average age of 44.4 ± 14.7 years compared to 39.62 ± 14.9 years in males, p < 0.001. Significantly higher rates of hypertension, diabetes mellitus, obesity, dementia, and thyroid cancer and lower rates of ischemic heart disease (22.3% vs. 27.3%, p < 0.001) were found among females. Females had a higher rate of cirrhosis, 2.3% vs. 1.9%, p < 0.001, and a lower rate of hepatocellular carcinoma, 0.4% vs. 0.5%, p < 0.001. In the multivariate analysis, a relationship between age, diabetes mellitus, and cirrhosis development were found among males and females. A lower age-adjusted mortality rate was found among females, 94.5/1000 vs. 116/1000 among males. In conclusion, older age at diagnosis, higher rates of hypertension, diabetes mellitus, obesity, cirrhosis, and a lower age-adjusted all-cause mortality rate were found among females with NAFLD.

12 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
NANaim Abu-Freha
Naim Abu-Freha
RGRachel Gouldner
Rachel Gouldner
BCBracha Cohen
Bracha Cohen
MGMichal Gordon
Michal Gordon
OSOrly Sagi
Orly Sagi
LZLevi Zohar
Levi Zohar
(1) Background: Fecal occult blood test (FOBT) is the modality of choice in most countries for colorectal cancer (CRC) screening. We aimed to investigate the risk factors for CRC among patients with a positive FOBT in real life. (2) Methods: This was a retrospective study that included patients who tested positive for FOBT. Data regarding the comorbidities and laboratories were collected and compared between CRC and non-CRC groups. (3) Results: Positive FOBT was found among 45,500 (5.36%) subjects and CRC was found in 1502 (3.3%). CRC patients were older, age 62.7 ± 7.15 years compared with 59.33 ± 7.3 years (p < 0.001), and had significantly higher rates of hypertension (48.4% vs. 44.7%, p = 0.002), iron-deficiency anemia (20.6% vs. 16.4, p < 0.001), family history of CRC (7.3% vs. 5.1%, p < 0.001), and previous CRC (6.5% vs. 0.3%, p < 0.001). Lower levels of hemoglobin, iron, and ferritin were found in the CRC group. Age, family history of CRC, and previous CRC were found to be significant risk factors for diagnosis of CRC after positive FOBT with OR of 1.057, 1.4, and 15.9, respectively. (4) Conclusions: Iron-deficiency anemia, family history of CRC, previous colorectal cancer, and low hemoglobin, iron, and ferritin levels should direct physicians to give high priority to colonoscopy scheduling.

10 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
JHJawad Hindy
Jawad Hindy
AMAmir Mari
Amir Mari
TRTova Rainis
Tova Rainis
GTGadeer Ali Taha
Gadeer Ali Taha
Background: Eosinophilic esophagitis (EoE) is a chronic, immune-mediated esophageal disorder characterized by Th2-driven inflammation. Clinically, it manifests as esophageal dysfunction, including dysphagia and food impaction, and is frequently associated with atopic comorbidities. Methods: Diagnosis is established via histologic confirmation of ≥15 eosinophils per high-power field (hpf) on esophageal biopsy. Clinical presentation varies, ranging from subtle dysphagia to severe complications necessitating urgent endoscopic intervention. Results: Disease progression is characterized by esophageal remodeling, encompassing fibrosis, angiogenesis, and muscular hypertrophy. Management strategies require individualized, long-term approaches aimed at symptom control and prevention of structural complications. Discussion: Advances in the last decade have refined diagnostic criteria, standardized endoscopic scoring systems, and introduced novel therapeutic agents, including biologics. This review synthesizes current evidence regarding epidemiology, clinical manifestations, diagnostics, and therapeutic strategies.